Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical... see more

TSXV:THNK - Post Discussion

Think Research Corporation > Management Circular is Out
View:
Post by dt_core on Mar 05, 2024 9:18am

Management Circular is Out

The circular for the Beedie offer is now on sedar. We learn a few things from it.

1. THNKs below expectation financial performance and poor balance sheet management is 100% due to the decisions of an incompetent SA and senior management team. The circular presents facts that cement this reality.

2. Beedie initially offered 0.39 cents per share in October 2023 however the Board dragged its feet ultimately resulting in a 0.28 cent offer that later was increased to 0.32 cent offer.

3. Financial performance weakness continued for the past 8 months due to BioPharma and Clinic 360. These two acquisitions have turned into total busts. Once again, the result of incompetent management.

4. The company has looked into selling both BioPharma and Clinic360 since April 2023 but management has yet to find a suitable buyer at a high enough price

5. Despite knowing that THNK was likely to end up being sold management continued to pull a grand total of $5M in convertible debt from Beedie. Yet more incompetence and outside the interest of shareholders. This also ended up reducing the purchase price Beedie offered

6. Go shop period: Thus far 34 potential buyers have been contacted and 5 have entered confidentiality agreements (menaing they are doing diligence on THNK). That's a really good response rate and in my opinion signals that their is real interest amongst a number of parties raising my expectations for a bid. No acquisition proposal has been recieved from these buyers but its still early. I suspect that any offer will materialize at the end of this week at the earliest but mid next week seems more likely. The go shop ends March 16th.

So where do we go from here? With 5 NDA's signed I'm happy to wait and see if additional bids materialize and I'm encouraged that the probability of that occuring is relatively high. I also think it's possible that Beedie sweetens the deal potentially up to their original offer price.
Comment by Possibleidiot01 on Mar 05, 2024 1:34pm
I appreciated the summary ; I'm surprised they posted this far in advance of a vote and wouldn't have looked myself at this time. The clock is ticking and you , or rather those 5 serious buyers , have given me some hope that maybe my 39 cent cost of capital can be reached. Management was wrong they acted decisively and lacking when they behaved indecisively , JMO
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities